share_log
Reuters ·  04/29 10:11

Annovis Bio Inc - Efficacy in Cgic Endpoint Was Not Reached Due to Limited Number of Patients and Short Trial Duration

Annovis Bio Inc-由於患者數量有限和試驗時間短,未達到Cgic終點的療效

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論